|
June 3, 2007--QIAGEN
N.V. is buying Digene Corp. for $1.6 billion. The
transaction combines QIAGEN's portfolio of sample and
assay technologies, including a broad panel of molecular
diagnostic tests, with Digene's position in HPV targeted
molecular diagnostic testing. It is anticipated that the
combined company will have over $350 million of molecular
diagnostics revenues and more than $800 million in
revenues overall in 2008. QIAGEN
See
also The
Baltimore Sun’s article on the merger.
|
